Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06839833 · ClinicalTrials.gov registry record · NA
APOL1 Genotyping CTA Clinical Performance Study
A NA study of APOL1-mediated Kidney Disease, sponsored by Almac Diagnostic Services.
- Recruiting
- Registry status
- NA
- Development phase
- 1,000
- Enrollment target
- 1
- Study location
NCT06839833 is a NA study of APOL1-mediated Kidney Disease that is actively recruiting participants, run by Almac Diagnostic Services. The registered enrollment target is 1,000 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06839833, a NA study of APOL1-mediated Kidney Disease, is actively recruiting participants, sponsored by Almac Diagnostic Services.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment. The study will use the APOL1 Genotyping CTA to test deoxyribonucleic acid (DNA) extracted from blood specimens to identify individuals who are homozygous or compound heterozygous for apolipoprotein L1 (APOL1) high-risk genotypes (G1 and G2).The individuals who are identified as being homozygous or compound heterozygous for the APOL1 high-risk genotypes are candidates for enrolment onto an pharmaceutical company-sponsored, Phase 2b clinical trial which is investigating the safety and efficacy of a synthetic antisense oligonucleotide (ASO) for the treatment of APOL1-mediated kidney disease (AMKD).
Conditions Studied
Interventions
- DIAGNOSTIC_TEST APOL1 Genotyping
Study Locations (1)
North Carolina
- Almac Diagnostic Services LLC - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2025-03-06 |
| Est. Completion | 2026-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06839833
The ClinicalTrials.gov registry entry for NCT06839833 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almac Diagnostic Services, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with APOL1-mediated Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which APOL1 Genotyping is the first listed.
NCT06839833 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT06839833 about?
NCT06839833 is a clinical study titled "APOL1 Genotyping CTA Clinical Performance Study". Clinical Performance Study SP2024001, is a prospective, interventional study to assess the clinical performance of the APOL1 Genotyping Clinical Trial Assay (CTA) in the intended use population and environment. The study will use the APOL1 Genotyping CTA to test deoxyribonucleic acid (DNA) extracted...
What is the current status of trial NCT06839833?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,000 participants. The study started on 2025-03-06. Estimated completion is 2026-03.
What conditions does trial NCT06839833 study?
This clinical trial studies the following conditions: APOL1-mediated Kidney Disease.
What interventions are being tested in trial NCT06839833?
The interventions under investigation include: APOL1 Genotyping (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06839833?
This trial is sponsored by Almac Diagnostic Services, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06839833 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for APOL1-mediated Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.